• Theriva Biologics’ third-quarter 2026 net loss narrowed 66% year over year to $1.47 million.
• Research and development expenses fell 76% to $612,000, primarily due to lower clinical trial and manufacturing expenses.
• Cash and cash equivalents totaled $8.5 million at September 30, with cash runway into Q1 2027.
• VIRAGE2 enrollment is expected to finish in Q4 2026, with initial data anticipated by Q3 2027.
• The October sale of SYN-004 and related assets brought $350,000 upfront, with potential milestones totaling $91 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120800OMX_____CNEWS_EN_GNW9875995_en) on November 12, 2026, and is solely responsible for the information contained therein.